This site is intended for health professionals only

EU backs Xiapex for Dupuytren’s contracture


Pfizer’s Xiapex has gained approval from the European Commission for the treatment of a potentially disabling condition of the hand called Dupuytren’s contracture.

The tendons of patients affected by Dupuytren’s contracture  tend to be shorter and thicker than those of healthy individuals, causing their fingers to curve inwards.

Pfizer has the marketing rights to sell Xiapex – the first injectable treatment approved by Europe for Dupuytren’s contracture – throughout Europe.

The treatment will reach some European markets by the end of the year.

Pfizer 2011

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine